DSIP

Overview

DSIP (delta sleep-inducing peptide) is a naturally occurring nonapeptide first isolated in 1977 from the cerebral venous blood of rabbits during electrically induced sleep. It was named for its apparent ability to increase delta-wave (slow-wave) activity on the EEG, and for decades it has been discussed as a candidate endogenous "sleep factor."

That historical name, however, overstates what the evidence actually supports. Across nearly five decades of study, DSIP's sleep-promoting effects have been inconsistent and difficult to reproduce, its physiological role is unknown, its biosynthetic origin (gene and precursor) has never been identified, and it has no confirmed receptor. Much of the literature is old, methodologically heterogeneous, and dominated by small animal studies. A frequently cited 2006 review summed up the situation by calling DSIP "a still unresolved riddle."

Chemistry and structure

DSIP is a small, amphiphilic nonapeptide (nine amino acids) with the sequence:

Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu (one-letter: WAGGDASGE)

The peptide is unmodified at its termini in its canonical form. Several analogs, including a phosphorylated derivative and N-terminally substituted variants, were synthesized in early research, partly because some analogs proved more stable and, in some assays, more active than the parent peptide.

History and discovery

DSIP emerged from the "humoral theory of sleep," the idea that a circulating substance accumulates and promotes sleep. In the 1960s and 1970s, Marcel Monnier and Guido Schoenenberger and colleagues in Basel, Switzerland, performed cross-circulation experiments in rabbits: blood from the cerebral venous outflow of rabbits in electrically induced sleep was dialyzed and the dialysate transferred to awake recipient rabbits, which then showed increased delta-wave EEG activity.

From this dialysate the group isolated, sequenced, and synthesized the responsible nonapeptide, reporting the comparison of the natural and synthetic peptide in Experientia in 1977 (Monnier et al.). They named it the delta sleep-inducing peptide.

The line of work that connected DSIP to sleep was never extended into a mechanistic account. As later reviewers noted, no DSIP gene, precursor protein, or dedicated receptor was ever isolated, leaving the original sleep claim resting largely on the early bioassays.

Proposed mechanisms

There is no well-defined receptor or mechanism of action for DSIP. This is one of the most important and most often overlooked facts about the peptide.

Mechanistic ideas that appear in the literature include:

• Modulation of adrenergic/monoaminergic transmission. The Graf and Kastin (1986) review noted that a possible mechanism involving modulation of adrenergic transmission "remains to be established."
• Interaction with endogenous opioid systems. Some chronic-pain and withdrawal reports proposed a "modulating" or "programming" interaction with opioid-peptidergic systems, but this was inferred from effects, not from direct receptor characterization.
• Antioxidant / stress-protective signaling. In rodent models, DSIP has been associated with increased activity of antioxidant enzymes (superoxide dismutase, catalase, glutathione peroxidase/reductase) — a downstream effect rather than a defined receptor mechanism.

The absence of an identified gene and receptor also means DSIP's status as a genuine endogenous signaling molecule, as opposed to a degradation product or assay artifact, has periodically been questioned.

Research and evidence

The evidence base is old, heterogeneous, and largely preclinical, with a small number of dated human studies. The sections below distinguish human from animal work and flag quality limitations throughout.

Sleep (inconsistent)

Despite the name, the sleep evidence is the weakest part of the DSIP story relative to expectations.

• Animal: The original rabbit bioassays reported increased delta-wave activity, and later rodent work explored slow-wave sleep and sleep-related growth hormone release. Effects varied by species (for example, more REM-related effects reported in cats), dose, and timing, and were not consistently reproducible.
• Human: Human sleep data are sparse. Double-blind work by Schneider-Helmert in the 1980s in chronic insomnia patients reported some improvements in sleep measures and daytime functioning after intravenous DSIP. However, sample sizes were small, the route was intravenous, and the findings were not followed by rigorous confirmatory trials. Other studies in normal subjects found only minor EEG effects.
• Overall: The 2006 Kovalzon and Strekalova review concluded that the sleep-factor hypothesis for native DSIP remained poorly documented and weak, noting that some apparent activity was associated with synthetic analogs rather than the natural peptide.

Stress, HPA axis, and antioxidant effects (mostly animal)

• A body of (largely Russian-language and Eastern European) preclinical research has framed DSIP as a "stress-limiting" or adaptogenic regulatory peptide. In rodents, DSIP has been reported to blunt stress responses and to shift the prooxidant–antioxidant balance toward antioxidant defense.
• For example, Shustanova et al. (2001) reported that pretreatment with DSIP restored the prooxidant–antioxidant balance in rats exposed to cold stress, normalizing enzyme activities and raising reduced glutathione.
• These are animal findings using varied models and endpoints; they have not been validated in controlled human trials.

Analgesia and chronic pain (dated clinical reports)

• A 1984 clinical pilot study (Larbig et al., European Neurology) administered DSIP intravenously to seven patients with chronic pain conditions (migraine, tension headache, tinnitus, psychogenic pain) and reported reduced pain in six of seven, with a concurrent reduction in depressive symptoms.
• This was a very small, uncontrolled pilot from the 1980s. Related reports explored DSIP in headache and in opioid/alcohol withdrawal. None of this work was developed into adequately powered, controlled trials, and it should be treated as historical and hypothesis-generating only.

Pharmacokinetics

• DSIP is rapidly degraded in blood. Graf et al. (1987) found that DSIP incubated in human or rat blood broke down quickly into fragments (including a tryptophan-like product), in a temperature-, time-, and species-dependent manner.
• Its effective half-life in plasma is very short (on the order of minutes), and its rapid disappearance after injection is attributed mainly to enzymatic degradation. Some analogs persisted longer, partly through aggregation, which was offered as one explanation for why analogs sometimes showed stronger effects than the parent peptide.
• This short systemic stability is a recurring complication for interpreting DSIP's reported effects.

Evidence summary

Status and regulation

DSIP is not an approved medicine, food ingredient, or dietary supplement in the United States, European Union, United Kingdom, or other major jurisdictions. It has never been approved by the FDA, EMA, or comparable regulators, and it has not completed modern clinical development.

In practice, DSIP is sold and handled as a research chemical ("for laboratory research use only"), and material marketed this way is not manufactured, tested, or labeled to pharmaceutical standards. Because it is not an approved product, claims made about it in commercial contexts are not backed by regulatory review.

Deltaran — the registered Russian DSIP medicine (now lapsed)

DSIP was, briefly, the basis of an actual registered Russian medicine — a fact the peptide community cites loosely. Checking it against the state register sharpens the picture in two honest ways.

• [Regulatory] Deltaran (Дельтаран) — a DSIP-based intranasal lyophilisate (0.3 mg) — was entered in the Russian State Register of Medicines (ГРЛС) under registration number LP-003849 (ЛП-003849), held by the "Komkon" research centre, on 20 September 2016. The active substance is the delta-sleep nonapeptide.
• Two caveats the marketing omits. First, its registered ATC class is N07BB — agents used in alcohol dependence and the correction of alcoholism/substance-abuse disorders, not a sleep or anti-ageing indication. Second, that registration was time-limited and lapsed in 2021, so "Deltaran is a registered Russian drug" is now past tense — there is no current active marketing authorisation on the register.

So DSIP did reach the status of a registered national medicine — for addiction-related use, briefly — but that is a historical regulatory fact, not evidence that intranasal DSIP is an effective or currently authorised sleep or longevity treatment.

Safety

The safety profile of DSIP in humans is poorly characterized. There has been no modern, systematic safety evaluation, and the available human exposure comes mainly from small, dated studies under medical supervision.

• No reliable data establish the safety of unsupervised use, of repeated dosing, or of long-term exposure.
• The purity, identity, and contaminant profile of material sold as a research chemical cannot be assumed to be controlled.
• Because no defined receptor or mechanism is known, off-target effects are difficult to predict.

The honest summary is that the absence of adverse-event reports reflects a lack of study, not a demonstration of safety.

Legal status

Legal status varies by country and can change. As a general picture as of this article's update:

• DSIP is not a scheduled controlled substance in most jurisdictions, but it is also not an approved drug or supplement, so it occupies a gray, research-only category.
• Selling or marketing it for human consumption, or making therapeutic claims, is generally prohibited under medicines and supplement regulations even where possession of research material is not specifically restricted.
• Anti-doping context: athletes should note that uncharacterized peptides and unapproved substances can fall under broad anti-doping prohibitions. Individuals subject to testing should consult current WADA guidance rather than assume a compound is permitted.

This section is informational and not legal advice; readers are responsible for the laws that apply to them.

How it compares

DSIP is something of an outlier among the neuropeptides documented here. Unlike Semax and Selank (synthetic analogues with defined nootropic/anxiolytic research programmes) or Cerebrolysin (an approved-abroad neurotrophic mixture), DSIP has no defined receptor, no established mechanism, and an inconsistent evidence base despite decades of study. Among this group it arguably has the weakest and most disputed support, a key point when comparing it to better-characterised compounds. See the Cognition, mood & sleep overview.

Common misconceptions

• "The name proves it induces deep sleep." The name reflects a 1970s bioassay observation, not a validated clinical effect. Native DSIP's sleep effects are inconsistent and, in the strictest reviews, weakly documented.
• "DSIP is a well-understood sleep hormone." It has no identified gene, precursor, or receptor, and its physiological role is unknown. It is not an established hormone in the way that, for example, melatonin is.
• "There is solid human clinical evidence." Human data are limited to small, mostly 1980s studies (sleep, pain, withdrawal), often without modern controls or replication.
• "It clearly works for pain / stress / longevity." Many of these claims trace to small pilot studies or to rodent experiments and have not been confirmed in rigorous human trials.
• "A short half-life doesn't matter." DSIP is degraded within minutes in blood, which itself complicates how, and whether, many reported systemic effects could occur.

Community claims & recent evidence

The points below address claims circulating in the peptide community — including popular video "masterclasses" — checked against the primary sources we could reach. A knowledgeable presenter is not peer review; every statement was treated as a claim to verify, not a fact. One honest limit applies throughout: not locating a citation in the sources we searched is not the same as showing a claim is false. A great deal of relevant work — paywalled journals, Russian-language and other regional literature, older pre-digital reports, conference material, and unpublished or clinical-practitioner data — is not indexed where we looked, so "we could not find it" should be read as a limit of our reach, not as disproof.

Verified additions

• DSIP stimulated growth hormone (and LH) release in rats. [Animal] Intraventricular DSIP raised GH through combined hypothalamic and pituitary (dopaminergic) actions, and separately stimulated LH — but not FSH — via a hypothalamic site (GH: Iyer & McCann, Peptides 1987; LH: Iyer & McCann, Brain Research Bulletin 1987). This is a genuine endocrine signal, but it is rodent data, not a demonstrated human effect.
• A modern rodent stroke study reported a functional benefit. [Animal] Intranasal DSIP given over 8 days accelerated recovery of motor coordination (rotarod) in Sprague-Dawley rats after focal stroke; notably, the reduction in infarct volume was not statistically significant (Tukhovskaya et al., Molecules 2021). It is one of the few post-2000 in-vivo signals, and still preclinical.
• Where rigorous human data do exist, they are mostly null. [Human] Controlled human infusions found DSIP did not alter growth hormone or prolactin secretion in healthy women (Giusti et al., Psychoneuroendocrinology 1993), and did not affect CRH- or meal-induced ACTH and cortisol (Späth-Schwalbe et al., Psychoneuroendocrinology 1995). These negative trials are an important, often-omitted part of the record.

Claims we could not corroborate

• "A 1974 Soviet discovery from rabbit brains, buried by Western medicine." The record we can trace shows DSIP was isolated, sequenced and named in 1977 by Swiss researchers (Monnier & Schoenenberger, Basel) from the cerebral venous blood of rabbits in electrically induced sleep (Monnier et al., Experientia 1977) — so the "1974 Russian discovery" framing does not match the documented history we could locate, and we found no evidence of suppression. The more ordinary reading is that interest faded because the sleep effect proved hard to reproduce. [Human/historical]
• "DSIP raises growth hormone about 60% by direct neuroendocrine modulation." The GH finding we can locate is rodent (Iyer & McCann, Peptides 1987) and reports no such percentage, and the controlled human studies we found reported no GH effect (Giusti et al., 1993). We could not trace the "60%" figure or the cited "Aaylor 1986" to any identifiable published human study — which is a limit of the literature we could access, not proof the underlying observation never happened. [Human data available to us point the other way]
• "It normalizes cortisol / the HPA axis (Kajama 2001)." The best controlled human test we could find reported that DSIP did not affect CRH- or meal-induced ACTH and cortisol (Späth-Schwalbe et al., Psychoneuroendocrinology 1995). We could not locate a "Kajama 2001" DSIP paper in the sources we searched, so we cannot verify that specific citation. [Human data available to us point the other way]
• "It cuts menopausal hot flashes about 60% and improves cardiovascular and lipid profiles in menopausal women." We found no published human trial of DSIP in menopause in the accessible literature, so we cannot corroborate the figures or the attached citation — this is an evidence gap in what we could reach, not a demonstration that the claim is false. DSIP's reported overlap with GnRH neurons is an anatomical/animal observation rather than a clinical outcome. [No source located]
• "It drives mitochondrial biogenesis via PGC-1α and UCP2 (Stresova 1995)." One element here is checkable on its own terms: PGC-1α was not described in the literature until 1998, so a 1995 paper could not have reported it, which makes that specific dating hard to reconcile. We found no DSIP study demonstrating PGC-1α or UCP2 upregulation in the sources we searched. The related Russian-language work we could locate (Shustanova et al., Biochemistry (Moscow) 2001) concerns antioxidant-enzyme activity in cold-stressed rats rather than mitochondrial biogenesis. [Anachronistic dating / not corroborated in accessible sources]
• "DSIP fixes the 'three biological failures of all disease' and reverses Alzheimer's, lupus, diabetes and aging." We found no primary source in the accessible literature supporting a cure-all or longevity claim, and could not resolve the named citations (e.g. "Myron 1989") in the sources we searched. DSIP also still has no identified gene, receptor, or mechanism and no controlled human efficacy we could locate for any of these conditions — so this reads as far beyond what the reachable evidence can support, which is different from being disproven. [Hypothesis / not corroborated in accessible sources]

Frequently asked questions

Is DSIP a "longevity peptide"?

No published evidence supports this. DSIP has no identified gene, receptor, or mechanism, and no human trial shows it extends lifespan or healthspan or prevents age-related disease [Hypothesis]. The "longevity" framing repackages a 1970s rabbit sleep bioassay as anti-aging, but the actual human record is thin and dated — and where controlled human trials exist, DSIP did nothing to growth hormone, prolactin, or cortisol [Human] (Giusti et al., 1993; Späth-Schwalbe et al., 1995). Treat "longevity peptide" as marketing language, not a demonstrated effect.

Did Russian scientists discover DSIP in 1974 and did Western medicine bury it?

No. DSIP was isolated, sequenced, and named in 1977 by Swiss researchers (Monnier and Schoenenberger, in Basel) from the cerebral venous blood of rabbits in electrically induced sleep [Human/historical] (Monnier et al., Experientia 1977) — not a 1974 Russian finding. It was never suppressed: interest faded because the sleep effect proved difficult to reproduce and no receptor or mechanism was ever identified, not because of a cover-up.

Does DSIP boost growth hormone by about 60%?

The only growth-hormone signal comes from rats, where intraventricular DSIP raised GH through hypothalamic and pituitary actions and reported no such percentage [Animal] (Iyer & McCann, Peptides 1987). Controlled human infusions found DSIP did not change growth hormone or prolactin at all [Human] (Giusti et al., 1993). The specific "60%" figure and the cited "Aaylor 1986" do not trace to any retrievable human paper.

Does DSIP treat menopause, hot flashes, or improve cholesterol in women?

No published human trial of DSIP in menopause exists, so claims of cutting hot flashes "by 60%" or improving cardiovascular and lipid profiles are unsupported, and the attached "Kajama 2001" citation does not resolve in the literature [No source]. The best controlled human test of DSIP on the stress axis found no effect on CRH- or meal-induced ACTH and cortisol [Human] (Späth-Schwalbe et al., Psychoneuroendocrinology 1995).

Does DSIP fix inflammation, insulin resistance, and mitochondrial (ATP) function — the "three biological failures" behind all disease?

There is no primary evidence that DSIP reverses inflammation, insulin resistance, or mitochondrial decline in humans, and the "three failures that cause every disease" model is a personal theory, not established science [Hypothesis]. The mitochondrial-biogenesis claim (PGC-1α/UCP2, "Stresova 1995") is anachronistic — PGC-1α was not described until 1998 — and no DSIP study demonstrates it [Unsupported]. The real Russian-language work only reported antioxidant-enzyme changes in cold-stressed rats [Animal] (Shustanova et al., Biochemistry (Moscow) 2001).

Do you have to cycle DSIP (e.g. 10 days on, 5 off) to avoid tolerance?

This advice assumes a known receptor that downregulates and an endogenous production loop that shuts off — but DSIP has no confirmed receptor, gene, or mechanism, so the tolerance-and-cycling rationale is speculative [Hypothesis]. We give no dosing or cycling protocols: DSIP is an unapproved research chemical with a poorly characterized human safety profile, and the absence of adverse-event reports reflects a lack of study, not a demonstration of safety.